月旦知識庫
 
  1. 熱門:
 
首頁 臺灣期刊   法律   公行政治   醫事相關   財經   社會學   教育   其他 大陸期刊   核心   重要期刊 DOI文章
篇名
肝內膽管癌-精準治療之發展
並列篇名
Development of Targeted Therapy in Intrahepatic Cholangiocarcinoma
作者 楊翊梅朱旆億
中文摘要 肝內膽管癌(Intrahepatic cholangiocarcinoma, iCCA)占所有膽管癌(Cholan-giocarcinoma, CCA)約 35% [1],且發生率有逐年上升的趨勢。由於目前尚無理想的生物標定物 (biomarker) 來進行診斷、預後評估和選擇治療藥物的參考,導致預後不甚理想,三年死亡率高達 80%。在遺傳變異和環境因素的相互作用之下,導致複雜的致癌機制,因此增加標靶治療發展的困難度。
除了已知的 TP53, KRAS, BRAF, EGFR, PI3CA, PTEN 突變,利用次世代定序(next-generation sequencing, NGS) 技術發現肝內膽管癌其他獨特的基因變異,包括體細胞突變、拷貝數變異、基因融合...等現象。藉由基因層面上的進一步瞭解,將有助於在臨床上的診斷和治療發展。
英文摘要 The molecular markers and carcinogenesis of cholangiocarcinoma (CCA) have not been thoroughly investigated. Survival rate remains relatively poor for these patients. Intrahepatic cholangiocarcinoma (iCCA) is a relatively uncommon tumor, representing 35% of all cholangiocarcinoma. Further understanding of the genomic aspect of iCCA with biomarker-driven clinical trials that match thera-pies to targets are urgently needed.
Pan-cancer oncogene mutations, including TP53, KRAS, BRAF, EGFR,PI3CA, PTEN, have also been identified in iCCA. Advances in sequencing tech-nologies such as next-generation sequencing (NGS) has extended our understand-ing of genetic heterogeneity in iCCA. Results from NGS technology might help identify genetic variation for targeted therapeutics. This article discusses how the recent achievements in cancer genomics may advance diagnosis and therapy that ultimately improve patient outcome.
起訖頁 132-137
關鍵詞 肝內膽管癌標靶治療次世代定序
刊名 秀傳醫學雜誌
出版單位 秀傳紀念醫院
期數 201612 (15:3-4期)
DOI 10.3966/156104972016121503007  複製DOI  DOI申請
QRCode
 



讀者服務專線:+886-2-23756688 傳真:+886-2-23318496
地址:臺北市館前路28 號 7 樓 客服信箱
Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄